



Emerging Roles of *Circ-ZNF609* in Multiple Human Diseases

Songbo Wang[†], Jiajin Wu[†], Zhongyuan Wang[†], Zixuan Gong, Yiyang Liu* and Zengjun Wang*

Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China

OPEN ACCESS

Edited by:

Deeparjan Paul,
Children's Hospital of Philadelphia,
United States

Reviewed by:

Chunlin Ou,
Central South University, China
Christos K. Kontos,
National and Kapodistrian University of
Athens, Greece
Gopal Pandi,
Madurai Kamaraj University, India

*Correspondence:

Yiyang Liu
liu820700@163.com
Zengjun Wang
zengjunwang@njmu.edu.cn

[†]These authors have contributed
equally to this work.

Specialty section:

This article was submitted to
RNA,
a section of the journal
Frontiers in Genetics.

Received: 16 December 2021

Accepted: 03 June 2022

Published: 22 July 2022

Citation:

Wang S, Wu J, Wang Z, Gong Z, Liu Y
and Wang Z (2022) Emerging Roles of
Circ-ZNF609 in Multiple
Human Diseases.
Front. Genet. 13:837343.
doi: 10.3389/fgene.2022.837343

Circular RNAs (circRNAs) are a special type of endogenous RNAs with extensive roles in multiple human diseases. They are formed by back-splicing of partial sequences of the parental precursor mRNAs. Unlike linear RNAs, their covalently closed loop structure without a 5' cap and a 3' polyadenylated tail confers on them high stability and they are difficult to be digested by RNase R. Increasing evidence has proved that aberrant expressions of many circRNAs are detected and that circRNAs exert essential biological functions in disease development and progression *via* acting as a molecular sponge of microRNA, interacting with proteins as decoys or scaffolds, or self-encoding small peptides. Circular RNA zinc finger protein 609 (*circ-ZNF609*) originates from exon2 of ZNF609, which is located at chromosome 15q22.31, and it has recently been proved that it can translate into a protein. Being aberrantly upregulated in various diseases, it could promote malignant progression of human tumors, as well as tumor cell proliferation, migration, and invasion. Here in this review, we concluded the biological functions and potential mechanisms of *circ-ZNF609* in multiple diseases, which could be further explored as a targetable molecule in future accurate diagnosis and prognosis.

Keywords: circular RNA, ZNF609, human diseases, tumor malignant progression, mechanism

INTRODUCTION

In 1976, circular RNAs (circRNAs) were found in viroids and eukaryotic cells (Kolakofsky, 1976; Sanger et al., 1976). In the process of transcription from parental gene to RNA, circular RNAs are back-spliced to form a loop structure without a 5' cap and a 3' polyadenylated tail (Jeck et al., 2012; Chen and Yang, 2015). The special circular structure endows them with a characteristic so that they can resist the digestion of exonuclease RNase R and become a class of relatively stable RNAs (Suzuki et al., 2006; Xiao and Wilusz, 2019).

With the development of high-throughput RNA sequencing and bioinformatics, the mechanisms and functions of circRNAs have been gradually elucidated (Memczak et al., 2013; Chen and Yang, 2015). According to the current research, circRNAs are generally divided into three subtypes: exonic circRNAs (ecircRNAs) (Jeck et al., 2012), exon-intron circRNAs (eicircRNAs) (Li et al., 2015), and intronic circRNAs (ciRNAs) (Zhang et al., 2013). The majority is ecircRNAs located in the cytoplasm mostly, and the other two exist in the nucleus mostly (Jeck et al., 2012; Zhang et al., 2013; Li et al., 2015). CircRNAs are ubiquitous in tissue cells, blood cells, serum, and exosomes (Salzman et al., 2012; Rong et al., 2019; Shi et al., 2020a). The primary functions of circRNAs are as follows: the ability to regulate the transcription of parental mRNAs (Li et al., 2015); acting as molecular sponges to regulate the expressions of target genes (Thomson and Dinger, 2016); binding to and sequestering proteins to regulate the expressions of the associated proteins (Kristensen et al., 2019; Chen, 2020); and translating into proteins to perform their functions (Legnini et al., 2017; Shi et al., 2020b). CircRNAs play important roles in the occurrence and development of human diseases, such as




FIGURE 1 | Biogenesis and biological functions of *circ-ZNF609*. **(A)** ZNF609 is located in chromosome 15q22.31 in humans; the red line indicates its approximate location. ZNF609 contains 10 exons, and the exon2 is spliced in reverse to form *circ-ZNF609*. The total length of *circ-ZNF609* is 874nt and contains a 753nt coding region, the promoter of *circ-ZNF609* is at position 128, and the terminator is at position 6. **(B)** *Circ-ZNF609* as a molecular sponge to adsorb microRNAs, reducing its binding to the 3' UTR of the target mRNA, and regulate gene expression. **(C)** *Circ-ZNF609* can be translated into a protein.

promoting cell proliferation, migration, and invasion in tumors, regulating drug resistance, and the progression of cardiovascular disease, as well as regulating neovascularization (Liu et al., 2017; Aufiero et al., 2019; Rossi et al., 2019; Li et al., 2020a; Xiao et al., 2020; Ding et al., 2021; Kim et al., 2021; Verduci et al., 2021).


Circular RNA zinc finger protein 609 (*circ-ZNF609*) is highly expressed in normal human neurons and maintains physiological functions (Rybak-Wolf et al., 2015; Legnini et al., 2017). It is differentially expressed in a variety of human diseases, as a competitive endogenous RNA to regulate target genes and affect disease progression. In the present review, we aim to gain insights into the relationship between *circ-ZNF609* and human diseases and provide a theoretical basis for clinical diagnosis and targeted therapy.

Structure and Biological Function of *Circ-ZNF609*

Circ-ZNF609 is a covalently closed circular RNA, which originates from the primary transcript of exon2 of ZNF609 located on chromosome 15q22.31. It is usually formed by back-splicing, a downstream splice-donor site is joined to an upstream splice-acceptor site, resulting in the loop structure of *circ-ZNF609* and containing a specific junction site. It contains 874 bp nucleotides (Legnini et al.,

2017); as a kind of circRNA that could be translated, its coding sequence contains 753 bp nucleotides, the start codon is located at position 128, and the stop codon is located at position 6 (**Figure 1**). There is one of the RNA binding proteins that can regulate the biogenesis of *circ-ZNF609*. Liu et al. (Liu et al., 2021a) reported that the expression of *circ-ZNF609* could be upregulated by RNA binding protein fused in sarcoma (FUS), which could modulate the back-splicing reaction (Liu et al., 2021a). The FUS protein could induce the splicing and circularization of *circ-ZNF609* by binding to the upstream exon2 of ZNF609 pre-mRNA (Liu et al., 2021a).

Considering the loop structure of *circ-ZNF609* without a 5' cap, its translation relies on a splicing-dependent/cap-independent manner (Legnini et al., 2017). However, Hung et al. (Ho-Xuan et al., 2020a) found that its translation may be originated from trans-splicing the byproducts of the overexpression of artificial circRNAs. They thought while performing functional studies of overexpression constructs of circRNA, it should be evaluated carefully (Ho-Xuan et al., 2020a). The primary biological function of *circ-ZNF609* was to act as a molecular sponge of endogenous microRNAs to sequester and inhibit the microRNA activity, which led to regulating the target gene expression (Chen, 2020; Xiao et al., 2020). As in hepatocellular carcinoma, *circ-ZNF609* inhibits *miR-15a-5p/15b-5p* expression and then elevates *GLI2* (a key protein molecule concerning the Hedgehog pathway) expression,



activating the Hedgehog pathway to promote hepatocellular carcinoma (HCC) proliferation and metastasis (He et al., 2020).

***Circ-ZNF609* in Multiple Human Cancers**

The present studies suggested that the main function of *circ-ZNF609* is the posttranscriptional regulation, by acting as a molecular sponge of target microRNA (Figure 2; Table 1). As a carcinogen, *circ-ZNF609* was abnormally upregulated in tumor tissues and cell lines. It also promoted tumor proliferation, migration, invasion, and other malignant phenotypes. The following content describes the molecular mechanisms of *circ-ZNF609* in human cancers, in order by cancer names.

Breast Cancer

Breast cancer is the most common cancer and the second leading cause of cancer lethality among women (DeSantis et al., 2017). In comparison with conventional surgery, neoadjuvant therapy has become a more widely used option, and novel targeted therapies play an important role in long-term disease control of metastatic breast cancer (Harbeck and Gnant, 2017). Being highly expressed in breast tumor tissues; *circ-ZNF609* leads to a poor outcome in the overall survival and is closely associated with lymph node metastasis and advanced TNM stage (Wang et al., 2018a). Wang et al. proved that *circ-ZNF609* knockdown inhibits the formation of malignant phenotypes of breast cancer cells and delays the tumor growth rate *in vivo*. It exerted biological function by sponging *miR145-5p*, which targeted oncogenic ribosomal protein S6 kinase, polypeptide 1 (*p70S6K1*), and promoted breast cancer progression (Wang et al., 2018a). They

demonstrated that *circ-ZNF609* regulated the *miR-145-5p/p70S6K1* axis and could become a potential posttreatment prognostic biomarker in breast cancer.

Cervical Cancer

Each year, more than 500,000 women are diagnosed with cervical cancer. Advances in radiotherapy technology have significantly reduced treatment-related toxicity (Cohen et al., 2019); however, the overall survival of metastatic cervical tumors is still poor. Gu et al. (Gu et al., 2021) found that *circ-ZNF609* was overexpressed in cervical cancer tissues and cell lines, and knockdown of *circ-ZNF609* suppresses the malignant phenotype of the tumor. *Circ-ZNF609* acted as the sponge of *miR-197-3p*, directly upregulating the expression of E2F transcription factor 6 (*E2F6*). The overexpression of *E2F6* can partially reverse the inhibition of cell proliferation, migration, and invasion caused by *circ-ZNF609* depletion (Gu et al., 2021). Their research suggested that the *circ-ZNF609/miR-197-3p/E2F6* regulatory axis proposed a new insight into the progression of cervical cancer.

Colorectal Cancer

Colorectal cancer is the third most commonly diagnosed cancer in males and the second in females (Torre et al., 2015). Exploring the potential diagnostic biomarkers of colorectal cancer is of great significance to contemporary medicine. Emerging evidence has shown the vital role of *circ-ZNF609* in colorectal cancer development and progression. The expression level of *circ-ZNF609* was reported to be positively correlated with GLI family zinc finger 1 (*GLI1*) and negatively correlated with

TABLE 1 | Mechanism of *circ-ZNF609* in human cancers.

Cancers	Expression Change	Targeted miRNAs	Targeted Genes	Tumor's progression	Clinicopathological Features	References
Breast cancer (BC)	Upregulated	miR-145-5p	p70S6K1	Promoting	Lymph node metastasis, advanced TNM stage, poor overall survival	Wang et al. (Wang et al., 2018a)
Cervical cancer (CC)	Upregulated	miR-197-3p	E2F6	Promoting	—	Gu et al. (Gu et al., 2021)
Colorectal cancer (CRC)	Upregulated	miR-150	GLI1	Promoting	Lymph node metastasis, Dukes stage	Wu et al. (Wu et al., 2018)
Gastric cancer (GC)	Upregulated	miR-483-3p	CDK6	Promoting	Advanced TNM stage, poor overall survival	Wu et al. (Wu et al., 2019)
Glioma (GM)	Upregulated	miR-1224-3p	PLK1	Promoting	Advanced clinical grade	Du et al. (Du et al., 2021)
		miR-134-5p	BTG-2	Promoting	—	Tong et al. (Tong et al., 2019)
Hepatocellular carcinoma (HCC)	Upregulated	miR-15a(b)-5p	GLI2	Promoting	—	He et al. (He et al., 2020)
		miR-342-3p	PAP2C	Promoting	Lymph node metastasis, advanced TNM stage, poor overall survival	Liao et al. (Liao et al., 2020)
Lung cancer (LC)	Upregulated	miR-142-3p	GNB2	Promoting	—	Liu et al. (Liu et al., 2021a)
		miR-623	FOXO1	Promoting	Lymph node metastasis, advanced TNM stage, poor overall survival	Wang et al. (Wang et al., 2021a)
		miR-1224-3p	ETV1	Promoting	—	Zuo et al. (Zuo et al., 2020)
Melanoma (MM)	Upregulated	miR-138-5p	SIRT7	Promoting	—	Liu et al. (Liu et al., 2021b)
Nasopharyngeal carcinoma (NPC)	Upregulated	miR-145	STMN1	Promoting	Lymph node metastasis, advanced clinical stage	Wang et al. (Wang et al., 2021b)
		miR-150-5p	SP1	Promoting	—	Zhu et al. (Zhu et al., 2019)
		miR-188	ELF2	Promoting	—	Li et al. (Li et al., 2020b)
		miR-338-3p	HRAS	Promoting	Poor overall survival	Liu et al. (Liu et al., 2021c)
Prostate cancer (PC)	Upregulated	miR-186-5p	YAP1/AMPK	Promoting	—	Jin et al. (Jin et al., 2019)
		miR-501-3p	HK2	Promoting	Advanced TNM stage, metastasis	Du et al. (Du et al., 2020)
Renal cell carcinoma (RCC)	Upregulated	miR-138-5p	FOXP4	Promoting	—	Xiong et al. (Xiong et al., 2019)
Rhabdomyosarcoma (RMS)	Upregulated	—	E2F1	Promoting	—	Rossi et al. (Rossi et al., 2019)

miR-150. In particular, it acted as a molecular sponge of *miR-150* to downregulate the expression of *GLI1* and then promoted colorectal cancer cell proliferation and migration (Wu et al., 2018). Later, Hung et al. (Ho-Xuan et al., 2020b) found that *circ-ZNF609* acted as an oncogene during colorectal cancer progression and metastasis. The overexpression of *circ-ZNF609* leads to increased tumor growth, while knockdown led to contrasting effects in mouse xenograft models. However, Zhang et al. (Zhang et al., 2019a) reported discrepant results that *circ-ZNF609* is downregulated in colorectal cancer tissues and patient serum samples, and it also induced cell apoptosis *via* upregulating *p53*. To summarize, the specific role and regulating mechanism of *circ-ZNF609* in colorectal cancer are still unclear, requiring further elucidation.

Gastric Cancer

Gastric cancer is the second leading cause of cancer-related deaths and the incidence ranks fourth worldwide, which

mainly relies on pathological examination (Torre et al., 2015; Sitarz et al., 2018). Surgical resection and chemotherapy are the principal treatment approaches; however, lymph node and distant metastases during advanced stages limit the therapeutic effect (Sitarz et al., 2018). Therefore, seeking early biomarkers of gastric cancer makes all the difference between accurate diagnosis and treatment (Zhang and Zhang, 2017). Wu et al. (Wu et al., 2019) proved that *circ-ZNF609* is overexpressed in cancer tissues and cell lines of gastric cancer patients, and it was positively correlated with a higher TNM stage and a lower 5-year survival rate. It acted as a sponge of *miR-483-3p*, upregulated the expression of cell-promoting factor cyclin-dependent kinase 6 (*CDK6*), and promoted the proliferation and migration of gastric cancer cells through the *circ-ZNF609/miR-483-3p/CDK6* axis (Wu et al., 2019). In interest, Liu et al. (Liu et al., 2019) had discovered different mechanisms of *circ-ZNF609* in gastric cancer, through binding to *miR-145-5p* and negatively regulating its expression. Knockdown of *circ-ZNF609* inhibited

cell proliferation and induced apoptosis, which could be partially reversed by *miR-145-5p* overexpression (Liu et al., 2019).

Glioma

Glioma is a primary brain tumor that is highly metastatic and aggressive (Weller et al., 2015; Chen et al., 2017). It is of great significance to determine the potential molecular mechanism of *circ-ZNF609* in glioma. Du et al. (Du et al., 2021) proved that *circ-ZNF609* was overexpressed in glioma tissues and cell lines and was significantly overexpressed in high-grade glioma than in low-grade glioma. Silencing *circ-ZNF609* could inhibit the proliferation and migration of glioma cells. In routine, it promoted the expression of polo-like kinase-1 (*PLK1*) by competitively binding to *miR-1224-3p*, and *circ-ZNF609* also promoted tumor growth *in vivo* (Du et al., 2021). Meanwhile, Tong et al. (Tong et al., 2019) found that *miR-134-5p* inhibited the expression of BTG antiproliferation factor 2 (*BTG-2*) and inhibited the proliferation and migration of glioma. *Circ-ZNF609* positively regulated the expression of *BTG-2* through competitively binding to *miR-134-5p*, leading to the proliferation and migration of glioma. It proposed a novel mechanism of *circ-ZNF609* in regulating the progression of glioma (Tong et al., 2019).

Hepatocellular Carcinoma

Liver cancer is the fourth leading cause of cancer deaths worldwide (Villanueva, 2019). Existing studies have demonstrated that circRNAs could promote the progress of HCC by regulating microRNAs (Zhang and Wang, 2021). *Circ-ZNF609* was highly expressed in HCC tissues and cell lines. Knockdown of *circ-ZNF609* could inhibit the proliferation, migration, and invasion of HCC and promote apoptosis (He et al., 2020). Adding SAG, an agonist of the Hedgehog signal pathway, could restore the phenotype caused by *circ-ZNF609* knockdown (He et al., 2020). Bioinformatics analysis and experiments validated that *circ-ZNF609* regulated the expressions of *miR-15a-5p/15b-5p* and GLI family zinc finger 2 (*GLI2*) and promoted the malignant phenotype of HCC through the Hedgehog pathway (He et al., 2020). Liao et al. (Liao et al., 2020) also proved that silencing *circ-ZNF609* could inhibit the proliferation of HCC and upregulate the expression of *RAP2C* (member of the RAS oncogene family) by acting as a sponge of *miR-342-3p*. The experiments *in vivo* showed that *circ-ZNF609* facilitated tumor growths, confirming the findings *in vitro*.⁴⁹

Lung Cancer

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer (Devesa et al., 2005), and circRNAs play a significant role in its pathogenesis and progression (Di et al., 2019; Huang et al., 2019). Fork head box protein M1 (*FOXM1*) is overexpressed in various cancers, which is a necessary transcription factor for cell proliferation (Liao et al., 2018). In NSCLC, it was targeted by *miR-623* and *circ-ZNF609*. Knocking down *circ-ZNF609* inhibited cell viability, migration, and invasion and promoted apoptosis, and knocking down *miR-623* or overexpressed *FOXM1* could weaken these effects

(Wang et al., 2021a). Lung adenocarcinoma (LUAD) is one of the histological subtypes of lung cancer with a poor prognosis (Devesa et al., 2005); *circ-ZNF609* was overexpressed in LUAD, acting as a sponge of *miR-1224-3p* to promote the cell proliferation of LUAD, which negatively regulated the expression of ETS variant transcription factor 1 (*ETV1*). They verified that *circ-ZNF609* promoted LUAD proliferation through the *miR-1224-3p/ETV1* axis (Zuo et al., 2020). In lung cancer, it was also found that FUS RNA binding protein could bind to the intron1 region of pre-mRNA of *ZNF609*, but not to exon1 and exon2. The specific binding may regulate the back-splicing of exon2, leading to upregulation of *circ-ZNF609* and promoting the malignant progression of lung cancer through the *miR-142-3p/GNB2* axis (Liu et al., 2021a). These studies provided different insights for understanding the value of *circ-ZNF609* in different histological subtypes of lung cancer, indicating that the pathogenic mechanism of *circ-ZNF609* in lung cancer was tissue specific.

Melanoma

Melanoma is a prevalent malignant skin cancer. Its incidence and mortality rates vary greatly worldwide. Once melanoma spreads, it will quickly become life-threatening (Schadendorf et al., 2018). As stated, *circ-ZNF609*-mediated DNA damage plays an important role in the development of melanoma. Knocking down *circ-ZNF609* could inhibit the proliferation, migration, and invasion of melanoma cell lines, reduce cell survival rate, and promote apoptosis (Liu et al., 2021b). Comet assays showed that the tail length was elevated and the expression level of γ H2AX variant histone (*γ H2AX*) was increased after *circ-ZNF609* depletion, suggesting that *circ-ZNF609* inhibited the DNA damage in melanoma (Liu et al., 2021b). *Circ-ZNF609* repressed DNA oxidative damage by acting as a sponge of *miR-138-5p*, which induced DNA oxidative damage by targeting sirtuin 7 (*SIRT7*). Adding *miR-138-5p* inhibitor or overexpression of *SIRT7* partially reversed the DNA damage phenotype caused by *circ-ZNF609* depletion, and *circ-ZNF609* depletion reduced the tumor size, tumor volume, and tumor weight through the *miR-138-5p/SIRT7* axis *in vivo* (Liu et al., 2021b). This study provided a new mechanism for the pathogenesis of DNA damage in melanoma, suggesting that circRNA-mediated DNA oxidative damage may be a valuable direction for melanoma biogenesis.

Nasopharyngeal Carcinoma

Nasopharyngeal carcinoma (NPC) is a common malignant tumor of the head and neck, and chemotherapy is an effective treatment method (Chen et al., 2019). However, since it is prone to lymph node metastasis and the degree of malignancy is high (Chua et al., 2016), it is of great significance to study the mechanism of occurrence and development. Pathological angiogenesis is a hallmark of cancer progression (Carmeliet and Jain, 2000), which is an important cause of the metastasis of NPC (Bao et al., 2018). The expression of vascular endothelial growth factor (VEGF) after the knockdown of *circ-ZNF609* in NPC cells was downregulated. The supernatant was added to treat human umbilical vein endothelial cells (HUVEC), and the proteins of

VEGF receptor-1 and VEGF receptor-2 in HUVECs are reduced. It could be observed that the total tube length was shortened, and the nodules were reduced when knocking down *circ-ZNF609* in HUVEC. These proved that the angiogenesis was reduced after knocking down *circ-ZNF609*. It negatively regulated the expression of *miR-145* and upregulated stathmin 1 (*STMN1*) to promote the proliferation, migration, and angiogenesis of NPC, forming a new regulatory mechanism for the pathological angiogenesis of NPC (Wang et al., 2021b). Zhu et al. (Zhu et al., 2019) found that *circ-ZNF609* promoted the growth and metastasis of NPC and exerted carcinogenic influence by competing with *miR-150-5p* which degraded *Sp1* expression. Liu et al. (Liu et al., 2021c) also proposed that *circ-ZNF609* was highly expressed in NPC tissues and cell lines, by binding to *miR-338-3p* to negatively regulate its expression, upregulating histidyl-tRNA synthetase (HARS) that promoted the proliferation, migration, invasion, and glycolysis of NPC, and xenograft experiments proved the result *in vitro*. The results of Li et al. (Li et al., 2020b) also showed that *circ-ZNF609* was overexpressed in NPC tissues and cell lines, knocking down it inhibited NPC cell proliferation and cell cycle transition, as well as accelerated apoptosis, and the carcinogenic effect was achieved through the *circ-ZNF609/miR-188/ELF2* axis. Their studies had shown that *circ-ZNF609* was overexpressed in NPC, as a molecular sponge of related microRNA and upregulated the expression of the target gene, achieving carcinogenic effects, and these suggest that *circ-ZNF609* may be a new therapeutic target for NPC. The molecular mechanism of *circ-ZNF609* in NPC had been inconsistently reached by different research teams, which may be caused by differences in patient samples. The mechanism of *circ-ZNF609* in NPC required a more rigorous study to reveal a clear conclusion.

Prostate Cancer

Prostate cancer is a common malignant tumor of the urinary system (Torre et al., 2015), and radiotherapy is the main treatment modality. However, the metastasis of advanced patients limits the application of radiotherapy (Mohler et al., 2010). It is of great significance to understand the mechanisms of radiological resistance. Even in the presence of oxygen and fully functional mitochondria, tumor cells increased glucose uptake and fermentation of glucose to lactate, and the process is called the Warburg effect. It is characterized by changes in glycolysis and metabolism, which can promote tumor metastasis (Liberti and Locasale, 2016). *Circ-ZNF609* was highly expressed in prostate cancer tissues and cells, and silencing it could repress cell viability, inhibit cell migration and invasion, and induce cell apoptosis (Du et al., 2020). *Circ-ZNF609* silencing decreased the glucose uptake and lactate product of tumor cells, and overexpression of *circ-ZNF609* could increase the radioresistance of cells. However, the radioresistance was significantly inhibited by the addition of glycolysis inhibitor 2-deoxy-D-glucose (2-DG), suggesting that *circ-ZNF609* promoted glycolysis to improve the radioresistance of cells (Du et al., 2020). *Circ-ZNF609* acted as a molecular sponge of *miR-501-3p*, and 2-DG could significantly inhibit the promotion of glycolysis by anti-*miR-501-3p*. The *circ-ZNF609/miR-501-3p* axis was targeted to

upregulate the expression of hexokinase 2 (*HK2*), a key enzyme of glycolysis, and then improved the radioresistance of tumor cells both *in vitro* and *in vivo* (Du et al., 2020). Jin et al. (Jin et al., 2019) proposed that silencing *circ-ZNF609* could restrain Yes1-associated transcriptional regulator (*YAP1*) and AMP-activated protein kinase (*AMPK*) signaling pathways by upregulating *miR-186-5p*, thereby inhibiting cell proliferation, migration, and invasion, and inducing apoptosis. In conclusion, *circ-ZNF609* could promote prostate cancer progression through multiple mechanisms, including regulated glycolysis and metabolism, promoting radioresistance and activating signaling pathways.

Renal Cell Carcinoma


Renal cell carcinoma (RCC) is a common tumor of the urinary system (Rini et al., 2009). Some ncRNAs have been proved to be involved in the biological process of kidney cancer, providing molecular targets for the treatment (Li et al., 2017; Wang et al., 2017; Shelar et al., 2018). Xiong et al. (Xiong et al., 2019) proved that *circ-ZNF609* represented a circular structure that was resistant to the digestion of RNase R. It was also overexpressed in renal cancer cell lines than in renal epithelial cells. By targeted binding to *miR-138-5p*, *circ-ZNF609* upregulated the expression of the transcription factor forkhead box P4 (*FOXP4*) and promoted the proliferation, migration, and invasion of renal cancer cells. Knocking down of *circ-ZNF609* inhibited the malignant phenotype in RCC (Xiong et al., 2019).

Rhabdomyosarcoma

RMS is a pediatric skeletal muscle malignancy that accounts for roughly 5% of all pediatric tumors (Egas-Bejar and Huh, 2014). Rhabdomyosarcoma in children is usually divided into two main histological subtypes, the embryonal rhabdomyosarcoma (ERMS) and the alveolar rhabdomyosarcoma (ARMS), and the latter has a generally worse prognosis (Egas-Bejar and Huh, 2014; Sun et al., 2015). Rossi et al. (Rossi et al., 2019) reported that *circ-ZNF609* was upregulated in biopsies from ERMS and ARMS. *Circ-ZNF609* knockdown induced a significant decrease in the p-Akt protein level, which modulated cell proliferation-related pathways and an alteration of the p-Rb/Rb ratio in an ERMS-derived cell line. The hypophosphorylated Rb protein could bind E2F transcription factor 1 (*E2F1*) to reduce the activation of S-phase transcription factors such as *TCF19* and *MCMs*, which caused a specific block of ERMS from the G1 to the S phase. Differently to ERMS, in the ARMS-derived cells, due to the lower p53 that was involved in cell cycle arrest, ARMS does not undergo G1-S arrested after the *circ-ZNF609* knockdown, which means that *circ-ZNF609* knockdown was not enough to significantly inhibit ARMS cell proliferation (Rossi et al., 2019).

Circ-ZNF609 in Other Human Diseases

Similar to the function in human tumors, *circ-ZNF609* also acted as a sponge of microRNAs in nontumor diseases (Figure 3; Table 2). In nontumor diseases, the expression level of *circ-ZNF609* had not been verified in the human tissues. On accounting for cell lines and animal models, researchers found that *circ-ZNF609* promoted cell proliferation and induced poor phenotypes in most nontumorous diseases. However, in coronary

**TABLE 2** | Mechanism of *circ-ZNF609* in other human diseases.

Diseases	Expression Change	Targeted miRNAs	Targeted genes	Diseases Progression	References
Coronary artery disease (CAD)	Downregulated	miR-138-5p ^a miR-150-5p ^a	AKT1 ^a Smad7 ^a	Inhibiting	Liang et al. (Liang et al., 2020)
Corneal neovascularization (CNV)	Upregulated	miR-184	p-AKT/VEGF	Promoting	Wu et al. (Wu et al., 2020)
Focal segmental glomerulosclerosis (FSGS)	Upregulated	miR-615-5p	COL1	Promoting	Cui et al. (Cui et al., 2020)
Hirschsprung's disease (HD)	Downregulated	miR-150-5p	AKT3	Inhibiting	Peng et al. (Peng et al., 2017)
Neuropathic pain (NPP)	Upregulated	miR-22-3p	ENO1	Promoting	Li et al. (Li et al., 2020c)
Pressure ulcer (PU)	Upregulated	miR-145	JNK/p38MAPK	Promoting	Ge and Gao (Ge and Gao, 2020)
Retinal neurodegeneration (RND)	Upregulated	miR-615	METRN	Promoting	Wang et al. (Wang et al., 2018b)
Retinal vascular dysfunction (RVD)	Upregulated	miR-615-5p	MEF2A	Promoting	Liu et al. (Liu et al., 2017)
T-cell acute lymphoblastic leukemia (T-ALL)	Upregulated	miR-181a-5p	LFNG	Promoting	Buratin et al. (Buratin et al., 2020)

^aBased on bioinformatics prediction and literature reports.

heart disease and Hirschsprung's disease, it was downregulated, representing an opposite function as a protective regulator. Therefore, we summarized the role of *circ-ZNF609* in nontumorous diseases but not only in human cancers here.

Coronary Artery Disease

Coronary artery disease (CAD) is the major cause of mortality globally (Dagenais et al., 2020), and the inflammatory response theory has been widely recognized in its pathogenic mechanism (Hansson, 2005). It has been reported that circRNAs were involved in several cardiovascular pathological processes (Wang et al., 2016; Shen et al., 2019). Compared with normal populations, the expression of *circ-ZNF609* was downregulated in CAD patients. Logistic analysis suggested that a low *circ-ZNF609*

level was an independent risk factor for CAD. Overexpression of *circ-ZNF609* in cells would cause the decrease of *IL-6* and *TNF- α* and an increase in *IL-10* expressions, suggesting its antiinflammatory effects, and could alleviate the development of CAD (Liang et al., 2020). Based on the bioinformatics prediction and the literature reports, researchers speculated that *circ-ZNF609* exerted a protective function in CAD by sponging microRNA and regulated the *miR-138-5p/AKT1* or *miR-150-5p/Smad7* axis to interrupt inflammation pathways.

Corneal Neovascularization

The cornea lacks blood vessels to ensure that light passes through the lens, and pathological corneal neovascularization derived from the corneal limbus which is filled with blood vessels can

affect the function of the transparent cornea and threaten vision (Feizi et al., 2017; Mobaraki et al., 2019). The study of corneal neovascularization by Wu et al. (Wu et al., 2020) suggested that in the rat corneal suture model, the overexpression of *circ-ZNF609* and a decrease of *miR-184* were observed in the corneal epithelia of rats after corneal suture surgery, and *circ-ZNF609* acted as a sponge of *miR-184* to regulate the *AKT/β-catenin/VEGF* signaling pathway and then promoted cell proliferation, migration *in vitro*, and angiogenesis *in vivo*.⁸⁴ Their study proved that inhibiting *circ-ZNF609* may be a new therapeutic method for the treatment of pathological corneal neovascularization. The role of *circ-ZNF609* in rat corneal neovascularization was different from that of human tumors; although there was no more cell line model to validate the finding, it could be validated in more animal models to ensure the conclusion.

Focal Segmental Glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS) is the main cause of kidney disease worldwide, and it is a complex syndrome that arises after podocyte injury in general (Rosenberg and Kopp, 2017). In the mice model of FSGS, the expression of *circ-ZNF609* was increased in biopsies compared to normal control mice. The expression of *circ-ZNF609* was positively correlated with the degree of podocyte destruction and renal fibrosis, but *miR-615-5p* was negatively correlated with *circ-ZNF609* (Cui et al., 2020). In mechanism, it acted as a molecular sponge of *miR-615-5p* to downregulate the expression of podocyte biomarkers *WT1* and upregulate fibrotic proteins including *COL1*, promoting the progression of FSGS (Cui et al., 2020). The expression of *circ-ZNF609* in the kidney was limited not only to RCC but also to FSGS, indicating that the scope of research could be extended to other nontumor sites. This study suggested that *circ-ZNF609* might be a potential biomarker for the diagnosis of kidney disease.

Hirschsprung's Disease

Hirschsprung's disease (HSCR) is caused by a lack of enteric nerve cells in the variable part of the distal intestine, and infants with related genetic changes usually develop intestinal obstruction a few days after birth (Kenny et al., 2010). The expression of *circ-ZNF609* was downregulated in HSCR compared with normal colon tissues and inhibited the proliferation and migration of HSCR cells. In mechanism, it downregulated the expression of AKT serine/threonine kinase 3 (*AKT3*) through acting as a sponge of *miR-150-5p* and promoted disease progression (Peng et al., 2017). However, Rossi et al. (Rossi et al., 2019) found that the expressions of *miR-150-5p* and *AKT3* were not affected by the downregulation of *circ-ZNF609*; therefore, the mechanism of *circ-ZNF609*-regulated HSCR progression needs further study.

Neuropathic Pain

The widely accepted definition of neuropathic pain is the pain caused by a lesion or disease of the somatosensory system (Colloca et al., 2017). Due to the aging of the global population, the increasing incidence of cancer, and the consequences of chemotherapy, neuropathic pain may become

more common (Colloca et al., 2017), and therefore finding its therapeutic targets has important clinical significance. The expression level of *miR-22-3p* was reduced in rat models with chronic constrictive injury and was involved in the progression of neuropathic pain, and *miR-22-3p* downregulation promoted neuropathic pain by targeting enolase 1 (*ENO1*) to regulate the expression of inflammatory factors (Li et al., 2020c). Li et al. (Li et al., 2020c) found that *circ-ZNF609* regulated the expression of inflammatory factors *TNF-α*, *IL-1*, and *IL-6* to promote neuropathic pain progression through the *miR-22-3p/ENO1* axis (Li et al., 2020c). Although it was inappropriate to quantify the neuropathic pain phenotype with the level of inflammatory factors, this paper provided a new molecular mechanism for *circ-ZNF609* in the regulation of inflammatory factors.

Pressure Ulcers

Pressure ulcers (PU) mostly occur in paralyzed and bedridden patients and are localized injuries to the skin and/or underlying tissues, usually over a bony prominence as a result of pressure combined with friction (Agrawal and Chauhan, 2012). PU are usually accompanied by skin oxidative damage, and drugs with antioxidant function are considered for treatment (Liu et al., 2018; Zhang et al., 2019b). In the PU model of HaCaT cells treated with H_2O_2 , the expression of *circ-ZNF609* was promoted in the model, and silencing of the expression of *circ-ZNF609* alleviated oxidative stress damage including the viability loss, apoptosis, and ROS generation of HaCaT cells, through inhibiting the *JNK* and *p38MAPK* signaling pathways via acting as the sponge of *miR-145* (Ge and Gao, 2020). The study in the model of PU provided new evidence for *circ-ZNF609* in oxidative stress damage.

Retinal Neurodegeneration

Glaucoma is mainly manifested by visual field loss and irreversible blindness caused by progressively retinal neurodegenerative diseases, and the death of retinal ganglion cells (RGC) and high intraocular pressure are pathophysiological characteristics (Almasieh et al., 2012; Danesh-Meyer and Levin, 2015). In the rat model, *circ-ZNF609* was significantly upregulated in the degeneration of the optic nerve induced by high intraocular pressure, and silencing it could inhibit the proliferation of RGC and optic nerve damage caused by high intraocular pressure (Wang et al., 2018b). Their previous studies suggested that *circ-ZNF609* acted as a sponge of *miR-615* to promote the proliferation of vascular endothelial cells. *Circ-ZNF609* in RGC also acted as a sponge of *miR-615* and then upregulated mentoring glial cell differentiation regulator (*METRN*) expression, promoting cell proliferation (Wang et al., 2018b). This study of *circ-ZNF609* provided new insight into circRNAs in the growth of nerves, and it reflected the breadth of the role of circRNAs.

Retinal Vascular Dysfunction

Vascular dysfunction is a hallmark of pathological angiogenesis and contributes to the progression of various diseases (Puro et al., 2016), the expression of circRNAs is dysregulated in

cardiovascular disease that is accompanied by vascular dysfunction, and endothelial cell regulation plays an important role in it (Eelen et al., 2015; Auferio et al., 2019). The retinal vascular system can be observed by noninvasive means, which can be used to investigate the mechanism of vascular dysfunction (Flammer et al., 2013). *Circ-ZNF609* promoted pathological angiogenesis and made endothelial cells more susceptible to oxidative stress and hypoxia (Liu et al., 2017; Wang et al., 2021b). Knocking down *circ-ZNF609* in the mouse model of oxygen-induced retinopathy did not affect the development of normal retinal vascular, while it reduced avascular area and reduced pathological retinal angiogenesis (Liu et al., 2017). The study revealed the mechanism of action for the *circ-ZNF609/miR-615-5p/MEF2A* axis in the mediation of vascular endothelial dysfunction, and since pathological angiogenesis is a hallmark of tumors, this study also verified that *circ-ZNF609* can cause tumors.

T-Cell Acute Lymphoblastic Leukemia

The expression level of circRNAs differs among normal blood cell types, but the expression in T-ALL is still unclear (Nicolet et al., 2018). RNA sequencing data from 25 T-ALL patients were analyzed and most circRNAs were found to be downregulated in expression in malignant T-ALL (Buratin et al., 2020). In particular, *circ-ZNF609* was overexpressed in immature T-ALL, knocking down *circ-ZNF609* inhibited cell proliferation and survival compared with normal control (Buratin et al., 2020). Bioinformatics analysis suggested that *circ-ZNF609* was bound to *miR-181a-5p* in immature T-ALL, which by targeting O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase (*LFNG*) to promote leukemogenic potential through the Notch1 signaling pathway in T-ALL (Buratin et al., 2020). With only the predicted results of the bioinformatics analysis available here, researchers could verify the molecular mechanism of *circ-ZNF609* in T-ALL through more cell experiments and animal experiments.

CONCLUSION AND FUTURE PROSPECTS

The present review described the basic biological functions of *circ-ZNF609* and systematically concluded its differential expression and its underlying molecular mechanism in human diseases. We found that the expression of *circ-ZNF609* in various cancer tissues was higher than in adjacent normal tissues and dysregulation in nontumor diseases. When *circ-ZNF609* is overexpressed in tumor tissues, it could result in poor overall survival, and it positively correlated with lymph node metastasis and advanced TNM or clinical stage. Relevant research on *circ-ZNF609* helped us understand the pathogenesis of many diseases, and it was proved that *circ-ZNF609* might be an effective and promising biomarker for diagnosis.

CircRNAs not only exist in human tissues and blood cells but are also differentially expressed in the serum and exosomes, playing an important role in disease progression (Devaux,

2017; Vea et al., 2018; Kristensen et al., 2019; Wang et al., 2019). Therefore, researchers can use the circRNAs in the patient's body fluid as a noninvasive molecular marker. Emerging circRNAs have become potential therapeutic targets for human diseases, and *circ-ZNF609* is one of them. In particular, *circ-ZNF609* is an RNA that can be translated into a protein, giving it a broader role. Nowadays, the COVID-19 epidemic is serious, and the mRNA-based vaccine still has its limitations (Alameh et al., 2020; Corbett et al., 2020). The loop structure of *circ-ZNF609* prevents its degradation and confers stronger stability to it compared with linear mRNA (Xiao and Wilusz, 2019). It is a promising research direction to develop a circRNA-based vaccine, by integrating an antigen-encoding sequence of COVID-19 into *circ-ZNF609*. The internal ribosomal entry site of *circ-ZNF609* confers the translational function, making it possible to express the antigen of COVID-19. Qu et al. (Qu et al., 2022) reported a circRNA vaccine that elicited potent neutralizing antibodies and T-cell responses in an animal model (Qu et al., 2022; Szabó et al., 2022). The above studies indicated that *circ-ZNF609* might become an effective and safe molecular platform against the epidemic.

In human diseases, it exerts functions through the *circ-ZNF609*-miRNA-mRNA network, and *circ-ZNF609* knockdown or overexpression of miRNA will inhibit the malignant phenotype of cancers. Therefore, knocking down *circ-ZNF609* by precise RNA interference (RNAi) or knocking out by CRISPR/Cas9-mediated circRNA knockout (Yang et al., 2018), developing miRNA inhibitors, could serve as potential therapeutic strategies for treatments of multiple human diseases. In comparison with Qian et al. (Qian et al., 2021), we comprehensively discussed the underlying molecular mechanism of *circ-ZNF609* in multiple human diseases and expanded the types of the disease in detail. In addition, we discussed future research directions in *circ-ZNF609*-dysregulated diseases. The possible function of *circ-ZNF609* in the prevention of the COVID-19 epidemic was also explored. We hope this study could help reveal the far-reaching clinical significance of *circ-ZNF609*.

AUTHOR CONTRIBUTIONS

SBW and JJW wrote and revised the manuscript. ZYW and YYL helped to draft the manuscript. ZXG and YYL participated in the revision of the review. ZJW designed the project. All of the authors read and approved the final manuscript.

FUNDING

This research was supported by the National Natural Science Foundation of China (Grant Nos. 81270685 and 81771640), the Project of Nanjing Science and Technology Committee (No. 201605001), and the "333" Project of Jiangsu Province (No. BRA2018083).

REFERENCES

- Agrawal, K., and Chauhan, N. (2012). Pressure Ulcers: Back to the Basics. *Indian J. Plast. Surg.* 45, 244–254. doi:10.4103/0970-0358.101287
- Alameh, M.-G., Weissman, D., and Pardi, N. (2020). Messenger RNA-Based Vaccines against Infectious Diseases. *Curr. Top. Microbiol. Immunol.* doi:10.1007/82_2020_202
- Almasieh, M., Wilson, A. M., Morquette, B., Cueva Vargas, J. L., and Di Polo, A. (2012). The Molecular Basis of Retinal Ganglion Cell Death in Glaucoma. *Prog. Retin. eye Res.* 31, 152–181. doi:10.1016/j.preteyeres.2011.11.002
- Auferio, S., Reckman, Y. J., Pinto, Y. M., and Creemers, E. E. (2019). Circular RNAs Open a New Chapter in Cardiovascular Biology. *Nat. Rev. Cardiol.* 16, 503–514. doi:10.1038/s41569-019-0185-2
- Bao, L., You, B., Shi, S., Shan, Y., Zhang, Q., Yue, H., et al. (2018). Metastasis-associated miR-23a from Nasopharyngeal Carcinoma-Derived Exosomes Mediates Angiogenesis by Repressing a Novel Target Gene TSGA10. *Oncogene* 37, 2873–2889. doi:10.1038/s41388-018-0183-6
- Buratin, A., Paganin, M., Gaffo, E., Dal Molin, A., Roels, J., Germano, G., et al. (2020). Large-scale Circular RNA Deregulation in T-ALL: Unlocking Unique Ectopic Expression of Molecular Subtypes. *Blood Adv.* 4, 5902–5914. doi:10.1182/bloodadvances.2020002337
- Carmeliet, P., and Jain, R. K. (2000). Angiogenesis in Cancer and Other Diseases. *Nature* 407, 249–257. doi:10.1038/35025220
- Chen, L.-L. (2020). The Expanding Regulatory Mechanisms and Cellular Functions of Circular RNAs. *Nat. Rev. Mol. Cell Biol.* 21, 475–490. doi:10.1038/s41580-020-0243-y
- Chen, L.-L., and Yang, L. (2015). Regulation of circRNA Biogenesis. *RNA Biol.* 12, 381–388. doi:10.1080/15476286.2015.1020271
- Chen, R., Smith-Cohn, M., Cohen, A. L., and Colman, H. (2017). Glioma Subclassifications and Their Clinical Significance. *Neurotherapeutics* 14, 284–297. doi:10.1007/s13311-017-0519-x
- Chen, Y.-P., Chan, A. T. C., Le, Q.-T., Blanchard, P., Sun, Y., and Ma, J. (2019). Nasopharyngeal Carcinoma. *Lancet* 394, 64–80. doi:10.1016/S0140-6736(19)30956-0
- Chua, M. L. K., Wee, J. T. S., Hui, E. P., and Chan, A. T. C. (2016). Nasopharyngeal Carcinoma. *Lancet* 387, 1012–1024. doi:10.1016/S0140-6736(15)00055-0
- Cohen, P. A., Jhingran, A., Oaknin, A., and Denny, L. (2019). Cervical Cancer. *Lancet* 393, 169–182. doi:10.1016/S0140-6736(18)32470-X
- Colloca, L., Ludman, T., Bouhassira, D., Baron, R., Dickenson, A. H., Yarnitsky, D., et al. (2017). Neuropathic Pain. *Nat. Rev. Dis. Prim.* 3, 17002. doi:10.1038/nrdp.2017.2
- Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., et al. (2020). SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness. *Nature* 586, 567–571. doi:10.1038/s41586-020-2622-0
- Cui, X., Fu, J., Luan, J., Qi, H., Jiao, C., Ran, M., et al. (2020). CircZNF609 Is Involved in the Pathogenesis of Focal Segmental Glomerulosclerosis by Sponging miR-615-5p. *Biochem. Biophysical Res. Commun.* 531, 341–349. doi:10.1016/j.bbrc.2020.07.066
- Dagenais, G. R., Leong, D. P., Rangarajan, S., Lanus, F., Lopez-Jaramillo, P., Gupta, R., et al. (2020). Variations in Common Diseases, Hospital Admissions, and Deaths in Middle-Aged Adults in 21 Countries from Five Continents (PURE): a Prospective Cohort Study. *Lancet* 395, 785–794. doi:10.1016/S0140-6736(19)32007-0
- Danesh-Meyer, H. V., and Levin, L. A. (2015). Glaucoma as a Neurodegenerative Disease. *J. Neuro-Ophthalmology* 35, S22–S28. doi:10.1097/wno.0000000000000293
- DeSantis, C. E., Ma, J., Goding Sauer, A., Newman, L. A., and Jemal, A. (2017). Breast Cancer Statistics, 2017, Racial Disparity in Mortality by State. *CA a cancer J. Clin.* 67, 439–448. doi:10.3322/caac.21412
- Devaux, Y. (2017). Transcriptome of Blood Cells as a Reservoir of Cardiovascular Biomarkers. *Biochimica Biophysica Acta (BBA) - Mol. Cell Res.* 1864, 209–216. doi:10.1016/j.bbamcr.2016.11.005
- Devesa, S. S., Bray, F., Vizcaino, A. P., and Parkin, D. M. (2005). International Lung Cancer Trends by Histologic Type: Male:Female Differences Diminishing and Adenocarcinoma Rates Rising. *Int. J. Cancer* 117, 294–299. doi:10.1002/ijc.21183
- Di, X., Jin, X., Li, R., Zhao, M., and Wang, K. (2019). CircRNAs and Lung Cancer: Biomarkers and Master Regulators. *Life Sci.* 220, 177–185. doi:10.1016/j.lfs.2019.01.055
- Ding, L., Wang, R., Shen, D., Cheng, S., Wang, H., Lu, Z., et al. (2021). Role of Noncoding RNA in Drug Resistance of Prostate Cancer. *Cell Death Dis.* 12. doi:10.1038/s41419-021-03854-x
- Du, S., Li, H., Lu, F., Zhang, S., and Tang, J. (2021). Circular RNA ZNF609 Promotes the Malignant Progression of Glioma by Regulating miR-1224-3p/PLK1 Signaling. *J. Cancer* 12, 3354–3366. doi:10.7150/jca.54934
- Du, S., Zhang, P., Ren, W., Yang, F., and Du, C. (2020). Circ-ZNF609 Accelerates the Radioresistance of Prostate Cancer Cells by Promoting the Glycolytic Metabolism through miR-501-3p/HK2 Axis. *Cmar* Vol. 12, 7487–7499. doi:10.2147/cmar.S257441
- Eelen, G., de Zeeuw, P., Simons, M., and Carmeliet, P. (2015). Endothelial Cell Metabolism in Normal and Diseased Vasculature. *Circ. Res.* 116, 1231–1244. doi:10.1161/circresaha.116.302855
- Egas-Bejar, D., and Huh, W. W. (2014). Rhabdomyosarcoma in Adolescent and Young Adult Patients: Current Perspectives. *Adolesc. Health Med. Ther.* 5, 115–125. doi:10.2147/AHMT.S44582
- Feizi, S., Azari, A. A., and Safapour, S. (2017). Therapeutic Approaches for Corneal Neovascularization. *Eye Vis. (Lond)* 4, 28–10. doi:10.1186/s40662-017-0094-6
- Flammer, J., Konieczka, K., Bruno, R. M., Virdis, A., Flammer, A. J., and Taddei, S. (2013). The Eye and the Heart. *Eur. heart J.* 34, 1270–1278. doi:10.1093/eurheartj/ehd023
- Ge, R., and Gao, G. (2020). Anti-antioxidant Impacts of circZNF609 Silence in HaCaT Cells through Regulating miR-145. *Artif. Cells, Nanomedicine, Biotechnol.* 48, 384–392. doi:10.1080/21691401.2019.1709863
- Gu, Q., Hou, W., Shi, L., Liu, H., Zhu, Z., and Ye, W. (2021). Circular RNA ZNF609 Functions as a Competing Endogenous RNA in Regulating E2F Transcription Factor 6 through Competitively Binding to microRNA-197-3p to Promote the Progression of Cervical Cancer Progression. *Bioengineered* 12, 927–936. doi:10.1080/21655979.2021.1896116
- Hansson, G. K. (2005). Inflammation, Atherosclerosis, and Coronary Artery Disease. *N. Engl. J. Med.* 352, 1685–1695. doi:10.1056/nejmra043430
- Harbeck, N., and Gnant, M. (2017). Breast Cancer. *Lancet* 389, 1134–1150. doi:10.1016/S0140-6736(16)31891-8
- He, Y., Huang, H., Jin, L., Zhang, F., Zeng, M., Wei, L., et al. (2020). CircZNF609 Enhances Hepatocellular Carcinoma Cell Proliferation, Metastasis, and Stemness by Activating the Hedgehog Pathway through the Regulation of miR-15a-5p/15b-5p and GLI2 Expressions. *Cell Death Dis.* 11, 358. doi:10.1038/s41419-020-2441-0
- Ho-Xuan, H., Glazar, P., Latini, C., Heizler, K., Haase, J., Hett, R., et al. (2020). Comprehensive Analysis of Translation from Overexpressed Circular RNAs Reveals Pervasive Translation from Linear Transcripts. *Nucleic Acids Res.* 48, 10368–10382. doi:10.1093/nar/gkaa704
- Ho-Xuan, H., Lehmann, G., Glazar, P., Gypas, F., Eichner, N., Heizler, K., et al. (2020). Gene Expression Signatures of a Preclinical Mouse Model during Colorectal Cancer Progression under Low-Dose Metronomic Chemotherapy. *Cancers* 13, 49. doi:10.3390/cancers13010049
- Huang, X., Zhang, W., and Shao, Z. (2019). Prognostic and Diagnostic Significance of circRNAs Expression in Lung Cancer. *J. Cell. Physiology* 234, 18459–18465. doi:10.1002/jcp.28481
- Jeck, W. R., Sorrentino, J. A., Wang, K., Slevin, M. K., Burd, C. E., Liu, J., et al. (2012). Circular RNAs Are Abundant, Conserved, and Associated with ALU Repeats. *Rna* 19, 141–157. doi:10.1261/rna.035667.112
- Jin, C., Zhao, W., Zhang, Z., and Liu, W. (2019). Silencing Circular RNA circZNF609 Restrains Growth, Migration and Invasion by Up-Regulating microRNA-186-5p in Prostate Cancer. *Artif. Cells, Nanomedicine, Biotechnol.* 47, 3350–3358. doi:10.1080/21691401.2019.1648281
- Kenny, S. E., Tam, P. K. H., and Garcia-Barcelo, M. (2010). Hirschsprung's Disease. *Seminars Pediatr. Surg.* 19, 194–200. doi:10.1053/j.sempedsurg.2010.03.004
- Kim, E., Kim, Y. K., and Lee, S.-J. V. (2021). Emerging Functions of Circular RNA in Aging. *Trends Genet.* 37, 819–829. doi:10.1016/j.tig.2021.04.014
- Kolakofofsky, D. (1976). Isolation and Characterization of Sendai Virus DI-RNAs. *Cell* 8, 547–555. doi:10.1016/0092-8674(76)90223-3

- Kristensen, L. S., Andersen, M. S., Stagsted, L. V. W., Ebbesen, K. K., Hansen, T. B., and Kjems, J. (2019). The Biogenesis, Biology and Characterization of Circular RNAs. *Nat. Rev. Genet.* 20, 675–691. doi:10.1038/s41576-019-0158-7
- Legnini, I., Di Timoteo, G., Rossi, F., Morlando, M., Briganti, F., Sthandier, O., et al. (2017). *Circ-ZNF609* Is a Circular RNA that Can Be Translated and Functions in Myogenesis. *Mol. Cell* 66, 22–37. e29. doi:10.1016/j.molcel.2017.02.017
- Li, J. K., Chen, C., Liu, J. Y., Shi, J. Z., Liu, S. P., Liu, B., et al. (2017). Long Noncoding RNA MRCAT1 Promotes Metastasis of Clear Cell Renal Cell Carcinoma via Inhibiting NPR3 and Activating P38-MAPK Signaling. *Mol. Cancer* 16, 111–114. doi:10.1186/s12943-017-0681-0
- Li, J., Sun, D., Pu, W., Wang, J., and Peng, Y. (2020). Circular RNAs in Cancer: Biogenesis, Function, and Clinical Significance. *Trends Cancer* 6, 319–336. doi:10.1016/j.trecan.2020.01.012
- Li, L., Luo, Y., Zhang, Y., Wei, M., Zhang, M., Liu, H., et al. (2020). CircZNF609 Aggravates Neuropathic Pain via miR-22-3p/ENO1 axis in CCI Rat Models. *Gene* 763, 145069. doi:10.1016/j.gene.2020.145069
- Li, M., Li, Y., and Yu, M. (2020). CircRNA ZNF609 Knockdown Suppresses Cell Growth via Modulating miR-188/ELF2 Axis in Nasopharyngeal Carcinoma. *Ott Vol.* 13, 2399–2409. doi:10.2147/ott.S234230
- Li, Z., Huang, C., Bao, C., Chen, L., Lin, M., Wang, X., et al. (2015). Exon-intron Circular RNAs Regulate Transcription in the Nucleus. *Nat. Struct. Mol. Biol.* 22, 256–264. doi:10.1038/nsmb.2959
- Liang, B., Li, M., Deng, Q., Wang, C., Rong, J., He, S., et al. (2020). CircRNA ZNF609 in Peripheral Blood Leukocytes Acts as a Protective Factor and a Potential Biomarker for Coronary Artery Disease. *Ann. Transl. Med.* 8, 741. doi:10.21037/atm-19-4728
- Liao, G.-B., Li, X.-Z., Zeng, S., Liu, C., Yang, S.-M., Yang, L., et al. (2018). Regulation of the Master Regulator FOXM1 in Cancer. *Cell Commun. Signal* 16, 57. doi:10.1186/s12964-018-0266-6
- Liao, X., Zhan, W., Tian, B., Luo, Y., Gu, F., and Li, R. (2020). Circular RNA ZNF609 Promoted Hepatocellular Carcinoma Progression by Upregulating PAP2C Expression via Sponging miR-342-3p. *Ott Vol.* 13, 7773–7783. doi:10.2147/OTT.S253936
- Liberti, M. V., and Locasale, J. W. (2016). The Warburg Effect: How Does it Benefit Cancer Cells? *Trends Biochem. Sci.* 41, 211–218. doi:10.1016/j.tibs.2015.12.001
- Liu, C., Yao, M.-D., Li, C.-P., Shan, K., Yang, H., Wang, J.-J., et al. (2017). Silencing of Circular RNA-Znf609 Ameliorates Vascular Endothelial Dysfunction. *Theranostics* 7, 2863–2877. doi:10.7150/thno.19353
- Liu, J., Rybakina, E. G., Korneva, E. A., and Noda, M. (2018). Effects of Derinat on Ischemia-Reperfusion-Induced Pressure Ulcer Mouse Model. *J. Pharmacol. Sci.* 138, 123–130. doi:10.1016/j.jphs.2018.08.013
- Liu, Q., Cui, W., Yang, C., and Du, L.-P. (2021). Circular RNA ZNF609 Drives Tumor Progression by Regulating the miR-138-5p/SIRT7 axis in Melanoma. *Aging* 13, 19822–19834. doi:10.18632/aging.203394
- Liu, S., Yang, N., Jiang, X., Wang, J., Dong, J., and Gao, Y. (2021). FUS-induced Circular RNA ZNF609 Promotes Tumorigenesis and Progression via Sponging miR-142-3p in Lung Cancer. *J. Cell Physiol.* 236, 79–92. doi:10.1002/jcp.29481
- Liu, Z., Pan, H. M., Xin, L., Zhang, Y., Zhang, W. M., Cao, P., et al. (2019). *Circ-ZNF609* Promotes Carcinogenesis of Gastric Cancer Cells by Inhibiting miRNA-145-5p Expression. *Eur. Rev. Med. Pharmacol. Sci.* 23, 9411–9417. doi:10.26355/eurrev_201911_19433
- Liu, Z., Liu, F., Wang, F., Yang, X., and Guo, W. (2021). CircZNF609 Promotes Cell Proliferation, Migration, Invasion, and Glycolysis in Nasopharyngeal Carcinoma through Regulating HRAS via miR-338-3p. *Mol. Cell Biochem.* 476, 175–186. doi:10.1007/s11010-020-03894-5
- Memczak, S., Jens, M., Elefsinioti, A., Torti, F., Krueger, J., Rybak, A., et al. (2013). Circular RNAs Are a Large Class of Animal RNAs with Regulatory Potency. *Nature* 495, 333–338. doi:10.1038/nature11928
- Mobaraki, M., Abbasi, R., Omidian Vandchali, S., Ghaffari, M., Moztafzadeh, F., and Mozafari, M. (2019). Corneal Repair and Regeneration: Current Concepts and Future Directions. *Front. Bioeng. Biotechnol.* 7. doi:10.3389/fbioe.2019.00135
- Mohler, J., Bahnson, R. R., Boston, B., Busby, J. E., D’Amico, A., Eastham, J. A., et al. (2010). Prostate Cancer. *J. Natl. Compr. Canc Netw.* 8, 162–200. doi:10.6004/jnccn.2010.0012
- Nicolet, B. P., Engels, S., Aglialoro, F., van den Akker, E., von Lindern, M., and Wolkers, M. C. (2018). Circular RNA Expression in Human Hematopoietic Cells Is Widespread and Cell-type Specific. *Nucleic Acids Res.* 46, 8168–8180. doi:10.1093/nar/gky721
- Peng, L., Chen, G., Zhu, Z., Shen, Z., Du, C., Zang, R., et al. (2017). Circular RNA ZNF609 Functions as a Competitive Endogenous RNA to Regulate AKT3 Expression by Sponging miR-150-5p in Hirschsprung’s Disease. *Oncotarget* 8, 808–818. doi:10.18632/oncotarget.13656
- Puro, D. G., Kohmoto, R., Fujita, Y., Gardner, T. W., and Padovani-Claudio, D. A. (2016). Bioelectric Impact of Pathological Angiogenesis on Vascular Function. *Proc. Natl. Acad. Sci. U.S.A.* 113, 9934–9939. doi:10.1073/pnas.1604757113
- Qian, Y., Li, Y., Li, R., Yang, T., Jia, R., and Ge, Y. Z. (2021). circ-ZNF609: A Potent circRNA in Human Cancers. *J. Cell Mol. Med.* 25, 10349–10361. doi:10.1111/jcmm.16996
- Qu, L., Yi, Z., Shen, Y., Lin, L., Chen, F., Xu, Y., et al. (2022). Circular RNA Vaccines against SARS-CoV-2 and Emerging Variants. *Cell* S0092-8674, 00394. doi:10.1016/j.cell.2022.03.044
- Rini, B. I., Campbell, S. C., and Escudier, B. (2009). Renal Cell Carcinoma. *Lancet* 373, 1119–1132. doi:10.1016/S0140-6736(09)60229-4
- Rong, D., Lu, C., Zhang, B., Fu, K., Zhao, S., Tang, W., et al. (2019). CircSMC3 Suppresses the Proliferation and Metastasis of Gastric Cancer by Acting as a Competitive Endogenous RNA through Sponging miR-296-5p. *Mol. Cancer* 18, 25. doi:10.1186/s12943-019-0958-6
- Rosenberg, A. Z., and Kopp, J. B. (2017). Focal Segmental Glomerulosclerosis. *Clin. J. Am. Soc. Nephrol.* 12, 502–517. doi:10.2215/cjn.05960616
- Rossi, F., Legnini, I., Megiorni, F., Colantoni, A., Santini, T., Morlando, M., et al. (2019). *Circ-ZNF609* Regulates G1-S Progression in Rhabdomyosarcoma. *Oncogene* 38, 3843–3854. doi:10.1038/s41388-019-0699-4
- Rybak-Wolf, A., Stottmeister, C., Glažar, P., Jens, M., Pino, N., Giusti, S., et al. (2015). Circular RNAs in the Mammalian Brain Are Highly Abundant, Conserved, and Dynamically Expressed. *Mol. Cell* 58, 870–885. doi:10.1016/j.molcel.2015.03.027
- Salzman, J., Gawad, C., Wang, P. L., Lacayo, N., and Brown, P. O. (2012). Circular RNAs Are the Predominant Transcript Isoform from Hundreds of Human Genes in Diverse Cell Types. *PLoS One* 7, e30733. doi:10.1371/journal.pone.0030733
- Sanger, H. L., Klotz, G., Riesner, D., Gross, H. J., and Kleinschmidt, A. K. (1976). Viroids Are Single-Stranded Covalently Closed Circular RNA Molecules Existing as Highly Base-Paired Rod-like Structures. *Proc. Natl. Acad. Sci. U.S.A.* 73, 3852–3856. doi:10.1073/pnas.73.11.3852
- Schadendorf, D., van Akkooi, A. C. J., Berking, C., Griewank, K. G., Gutzmer, R., Hauschild, A., et al. (2018). Melanoma. *Lancet* 392, 971–984. doi:10.1016/S0140-6736(18)31559-9
- Shelar, S., Shim, E.-H., Brinkley, G. J., Kundu, A., Carobbio, F., Poston, T., et al. (2018). Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer. *Clin. Cancer Res.* 24, 6433–6446. doi:10.1158/1078-0432.ccr-18-1727
- Shen, L., Hu, Y., Lou, J., Yin, S., Wang, W., Wang, Y., et al. (2019). CircRNA-0044073 I-s U-preregulated in Atherosclerosis and I-ncreases the P-roliferation and I-nvasion of C-ells by T-arargeting miR-107. *Mol. Med. Rep.* 19, 3923–3932. doi:10.3892/mmr.2019.10011
- Shi, X., Wang, B., Feng, X., Xu, Y., Lu, K., and Sun, M. (2020). circRNAs and Exosomes: A Mysterious Frontier for Human Cancer. *Mol. Ther. - Nucleic Acids* 19, 384–392. doi:10.1016/j.omtn.2019.11.023
- Shi, Y., Jia, X., and Xu, J. (2020). The New Function of circRNA: Translation. *Clin. Transl. Oncol.* 22, 2162–2169. doi:10.1007/s12094-020-02371-1
- Sitarz, R., Skierucha, M., Mielko, J., Offerhaus, J., Maciejewski, R., and Polkowski, W. (2018). Gastric Cancer: Epidemiology, Prevention, Classification, and Treatment. *Cmar Vol.* 10, 239–248. doi:10.2147/CMAR.S149619
- Sun, X., Guo, W., Shen, J. K., Mankin, H. J., Hornicek, F. J., and Duan, Z. (2015). *Rhabdomyosarcoma: Advances in Molecular and Cellular Biology.* Sarcoma 2015.
- Suzuki, H., Zuo, Y., Wang, J., Zhang, M. Q., Malhotra, A., and Mayeda, A. (2006). Characterization of RNase R-Digested Cellular RNA Source that Consists of Lariat and Circular RNAs from Pre-mRNA Splicing. *Nucleic Acids Res.* 34, e63. doi:10.1093/nar/gkl151
- Szabó, G. T., Mahiny, A. J., and Vlatkovic, I. (2022). COVID-19 mRNA Vaccines: Platforms and Current Developments. *Mol. Ther.* 30 (5), 1850–1868. doi:10.1016/j.ymthe.2022.02.016

- Thomson, D. W., and Dinger, M. E. (2016). Endogenous microRNA Sponges: Evidence and Controversy. *Nat. Rev. Genet.* 17, 272–283. doi:10.1038/nrg.2016.20
- Tong, H., Zhao, K., Wang, J., Xu, H., and Xiao, J. (2019). CircZNF609/miR-134-5p/BTG-2 axis Regulates Proliferation and Migration of Glioma Cell. *J. Pharm. Pharmacol.* 72, 68–75. doi:10.1111/jphp.13188
- Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., and Jemal, A. (2015). Global Cancer Statistics, 2012. *CA A Cancer J. Clin.* 65, 87–108. doi:10.3322/caac.21262
- Vea, A., Llorente-Cortes, V., and de Gonzalo-Calvo, D. (2018). Circular RNAs in Blood. *Circ. RNAs*, 119–130. doi:10.1007/978-981-13-1426-1_10
- Verduci, L., Tarcitano, E., Strano, S., Yarden, Y., and Blandino, G. (2021). CircRNAs: Role in Human Diseases and Potential Use as Biomarkers. *Cell Death Dis.* 12, 468. doi:10.1038/s41419-021-03743-3
- Villanueva, A. (2019). Hepatocellular Carcinoma. *N. Engl. J. Med.* 380, 1450–1462. doi:10.1056/NEJMr1713263
- Wang, F., Li, X., Jia, X., and Geng, L. (2021). CircRNA ZNF609 Knockdown Represses the Development of Non-small Cell Lung Cancer via miR-623/FOXO1 Axis. *Cmar Vol.* 13, 1029–1039. doi:10.2147/CMAR.S282162
- Wang, J.-J., Liu, C., Shan, K., Liu, B.-H., Li, X.-M., Zhang, S.-J., et al. (2018). Circular RNA-Znf609 Regulates Retinal Neurodegeneration by Acting as miR-615 Sponge. *Theranostics* 8, 3408–3415. doi:10.7150/thno.25156
- Wang, J., Lin, Y., Jiang, D. H., Yang, X., and He, X. G. (2021). CircRNA ZNF609 Promotes Angiogenesis in Nasopharyngeal Carcinoma by Regulating miR -145/STMN1 axis. *Kaohsiung J. Med. Sci.* 37, 686–698. doi:10.1002/kjm.212381
- Wang, K., Long, B., Liu, F., Wang, J.-X., Liu, C.-Y., Zhao, B., et al. (2016). A Circular RNA Protects the Heart from Pathological Hypertrophy and Heart Failure by Targeting miR-223. *Eur. Heart J.* 37, 2602–2611. doi:10.1093/eurheartj/ehv713
- Wang, K., Sun, Y., Tao, W., Fei, X., and Chang, C. (2017). Androgen Receptor (AR) Promotes Clear Cell Renal Cell Carcinoma (ccRCC) Migration and Invasion via Altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 Signals. *Cancer Lett.* 394, 1–12. doi:10.1016/j.canlet.2016.12.036
- Wang, S., Xue, X., Wang, R., Li, X., Li, Q., Wang, Y., et al. (2018). CircZNF609 Promotes Breast Cancer Cell Growth, Migration, and Invasion by Elevating p70S6K1 via Sponging miR-145-5p. *Cmar Vol.* 10, 3881–3890. doi:10.2147/CMAR.S174778
- Wang, Y., Liu, J., Ma, J., Sun, T., Zhou, Q., Wang, W., et al. (2019). Exosomal circRNAs: Biogenesis, Effect and Application in Human Diseases. *Mol. Cancer* 18, 116–126. doi:10.1186/s12943-019-1041-z
- Weller, M., Wick, W., Aldape, K., Brada, M., Berger, M., Pfister, S. M., et al. (2015). Glioma. *Nat. Rev. Dis. Prim.* 1, 15017. doi:10.1038/nrdp.2015.17
- Wu, L., Xia, J., Yang, J., Shi, Y., Xia, H., Xiang, X., et al. (2018). Circ-ZNF609 Promotes Migration of Colorectal Cancer by Inhibiting Gli1 Expression via microRNA-150. *J. buon* 23, 1343–1349.
- Wu, P., Zhang, D., Geng, Y., Li, R., and Zhang, Y. (2020). Circular RNA-Znf609 Regulates Corneal Neovascularization by Acting as a Sponge of miR-184. *Exp. Eye Res.* 192, 107937. doi:10.1016/j.exer.2020.107937
- Wu, W., Wei, N., Shao, G., Jiang, C., Zhang, S., and Wang, L. (2019). circZNF609 Promotes the Proliferation and Migration of Gastric Cancer by Sponging miR-483-3p and Regulating CDK6. *Ott Vol.* 12, 8197–8205. doi:10.2147/OTT.S193031
- Xiao, M.-S., Ai, Y., and Wilusz, J. E. (2020). Biogenesis and Functions of Circular RNAs Come into Focus. *Trends Cell Biol.* 30, 226–240. doi:10.1016/j.tcb.2019.12.004
- Xiao, M.-S., and Wilusz, J. E. (2019). An Improved Method for Circular RNA Purification Using RNase R that Efficiently Removes Linear RNAs Containing G-Quadruplexes or Structured 3' Ends. *Nucleic Acids Res.* 47, 8755–8769. doi:10.1093/nar/gkz576
- Xiong, Y., Zhang, J., and Song, C. (2019). CircRNA ZNF609 Functions as a Competitive Endogenous RNA to Regulate FOXP4 Expression by Sponging miR-138-5p in Renal Carcinoma. *J. Cell. Physiology* 234, 10646–10654. doi:10.1002/jcp.27744
- Yang, J., Meng, X., Pan, J., Jiang, N., Zhou, C., Wu, Z., et al. (2018). CRISPR/Cas9-mediated Noncoding RNA Editing in Human Cancers. *RNA Biol.* 15 (1), 35–43. doi:10.1080/15476286.2017.1391443
- Zhang, X.-y., and Zhang, P.-y. (2017). Gastric Cancer: Somatic Genetics as a Guide to Therapy. *J. Med. Genet.* 54, 305–312. doi:10.1136/jmedgenet-2016-104171
- Zhang, X., Xue, H., Zhou, P., Liu, L., Yu, J., Dai, P., et al. (2019). RETRACTED: Angelica Polysaccharide Alleviates Oxidative Response Damage in HaCaT Cells through Up-Regulation of miR-126. *Exp. Mol. Pathology* 110, 104281. doi:10.1016/j.yexmp.2019.104281
- Zhang, X., Zhao, Y., Kong, P., Han, M., and Li, B. (2019). Expression of circZNF609 Is Down-Regulated in Colorectal Cancer Tissue and Promotes Apoptosis in Colorectal Cancer Cells by Upregulating P53. *Med. Sci. Monit.* 25, 5977–5985. doi:10.12659/MSM.915926
- Zhang, Y., and Wang, Y. (2021). Circular RNAs in Hepatocellular Carcinoma: Emerging Functions to Clinical Significances. *Front. Oncol.* 11. doi:10.3389/fonc.2021.667428
- Zhang, Y., Zhang, X.-O., Chen, T., Xiang, J.-F., Yin, Q.-F., Xing, Y.-H., et al. (2013). Circular Intronic Long Noncoding RNAs. *Mol. Cell* 51, 792–806. doi:10.1016/j.molcel.2013.08.017
- Zhu, L., Liu, Y., Yang, Y., Mao, X. M., and Yin, Z. D. (2019). CircRNA ZNF609 Promotes Growth and Metastasis of Nasopharyngeal Carcinoma by Competing with microRNA-150-5p. *Eur. Rev. Med. Pharmacol. Sci.* 23, 2817–2826. doi:10.26355/eurrev_201904_17558
- Zuo, Y., Shen, W., Wang, C., Niu, N., and Pu, J. (2020). Circular RNA Circ-Znf609 Promotes Lung Adenocarcinoma Proliferation by Modulating miR-1224-3p/ETV1 Signaling. *Cmar Vol.* 12, 2471–2479. doi:10.2147/CMAR.S232260

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wang, Wu, Wang, Gong, Liu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.